---
title: Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma
nct_id: NCT03107962
overall_status: UNKNOWN
phase: PHASE2
sponsor: Mingzhi Zhang
study_type: INTERVENTIONAL
primary_condition: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03107962.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03107962"
ct_last_update_post_date: 2017-04-11
last_seen_at: "2026-05-12T07:00:49.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

**Official Title:** PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma

**NCT ID:** [NCT03107962](https://clinicaltrials.gov/study/NCT03107962)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Mingzhi Zhang
- **Conditions:** Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
- **Start Date:** 2017-02-19
- **Completion Date:** 2018-12
- **CT.gov Last Update:** 2017-04-11

## Brief Summary

The purpose of this study is to evaluate the efficacy and safety of PD-1 blockade pembrolizumab for patients with relapsed or refractory Natural Killer(NK)/T Cell Lymphoma.

## Detailed Description

Patients with relapsed or refractory NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy. The investigators have been proceeding this trial to evaluate the efficacy and safety of the immune checkpoint inhibitor PD-1 blockade, pembrolizumab in the patients with relapsed or refractory NK/T cell lymphoma.

## Eligibility

- **Minimum age:** 14 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time \> 3 months
* Histological confirmed evidence of relapsed or refractory NK/T cell lymphoma
* Before enrollment, representative formalin-fixed paraffin-embedded tumor samples (or 15 tissue sections at least) and related pathological reports are needed
* Previous treatment with at least one chemotherapy regimen
* At least one measurable lesion
* None of other serious diseases, cardiopulmonary function is normal
* Pregnancy test of women at reproductive age must be negative
* Patients could be followed up
* None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments.
* volunteers who signed informed consent.
* No anti-PD1 antibody contraindication (All of the following tests are required to be finished within 14 days prior to the first research): 2.5×109/L\<WBC\<15×109/L, hemoglobin ≥ 90 g/L, neutrophil≥ 1.5×109/L, lymphocyte≥0.5×109/L, platelet ≥ 100×109/L, serum albumin≥2.5g/dL, ALT and AST ≤ 2×ULN, serum bilirubin≤ 1.5×ULN, serum creatine ≤ 1.5×ULN, Serum Albumin ≥ 30g/L, serum plasminogen is normal, creatinine clearance rate≥30 mL/min, INR≤1.5×ULN, APTT≤1.5×ULN

Exclusion Criteria:

* Disagreement on blood sample collection
* Patients allergic of chimeric or humanized antibody
* Pregnant or lactating women
* Serious medical illness likely to interfere with participation
* Serious infection
* Primitive or secondary tumors of central nervous system
* The evidence of CNS metastasis
* History of peripheral nervous disorder or dysphrenia
* History of active autoimmune disease and a concomitant second cancer
* patients participating in other clinical trials
* patients taking other antitumor drugs
* patients estimated to be unsuitable by investigator
```

## Arms

- **PD-1 Blocking Antibody** (EXPERIMENTAL) — Pembrolizumab

## Interventions

- **Pembrolizumab (PD-1 Blocking Antibody)** (DRUG) — pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.

## Primary Outcomes

- **Response rate** _(time frame: every 6 weeks, up to completion of treatment (approximately 18 weeks, unless the disease progresses or patients cannot tolerate the drug))_ — 21 days (3 weeks) for one cycle, Efficacy was evaluated every two cycles.

## Secondary Outcomes

- **Progression-free survival** _(time frame: up to end of follow-up-phase (approximately 24 months))_
- **Overall survival** _(time frame: up to the date of death (approximately 3 years))_
- **Median survival time** _(time frame: 2 years)_

## Locations (1)

- Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.oncology department of the first affiliated hospital of zhengzhou university|zhengzhou|henan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03107962.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03107962*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*